KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Long-Term Deferred Tax (2016 - 2025)

Boston Scientific's Long-Term Deferred Tax history spans 16 years, with the latest figure at $3.7 billion for Q4 2024.

  • For Q4 2024, Long-Term Deferred Tax fell 4.84% year-over-year to $3.7 billion; the TTM value through Dec 2024 reached $3.7 billion, down 4.84%, while the annual FY2024 figure was $3.7 billion, 4.84% down from the prior year.
  • Long-Term Deferred Tax for Q4 2024 was $3.7 billion at Boston Scientific, down from $3.8 billion in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $4.2 billion in Q4 2020 and bottomed at $3.7 billion in Q4 2024.
  • The 5-year median for Long-Term Deferred Tax is $4.0 billion (2021), against an average of $4.0 billion.
  • The largest annual shift saw Long-Term Deferred Tax rose 0.57% in 2022 before it fell 4.84% in 2024.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $4.2 billion in 2020, then dropped by 1.62% to $4.1 billion in 2021, then dropped by 4.83% to $3.9 billion in 2022, then decreased by 2.56% to $3.8 billion in 2023, then decreased by 4.84% to $3.7 billion in 2024.
  • Per Business Quant, the three most recent readings for BSX's Long-Term Deferred Tax are $3.7 billion (Q4 2024), $3.8 billion (Q2 2024), and $3.8 billion (Q4 2023).